^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SMO W535L

    i
    Other names: SMO, Smoothened Frizzled Class Receptor, Smoothened Seven Transmembrane Spanning Receptor, Smoothened Frizzled Family Receptor, Frizzled Family Member 11, Smoothened Homolog, Protein Gx, SMOH, Seven Transmembrane Helix Receptor, Smoothened (Drosophila) Homolog, Smoothened Homolog (Drosophila), FZD11, CRJS, Gx
    Entrez ID:
    6608
    Related biomarkers:
    Mutation
    over1year
    Whole-exome sequencing of secondary tumors arising from nevus sebaceous revealed additional genomic alterations besides RAS mutations. (PubMed, J Dermatol)
    In conclusion, our study revealed that secondary tumors arising from NS harbor known RAS hotspot mutations and additional genomic alterations, including putative driver mutations and PTCH1 copy-loss. These results could help to define the high-risk group for tumor development in patients with NS and provide evidence for prophylactic resection.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • PTCH1 (Patched 1) • RAS (Rat Sarcoma Virus)
    |
    TP53 mutation • KRAS G12C • KRAS G12D • RAS mutation • HRAS G13R • KRAS G12 • NRAS Q61R • PTCH1 mutation • KRAS G13 • NRAS G12 • HRAS G12C • HRAS Q61R • HRAS G13R • SMO W535L • TP53 R213
    over1year
    Correlation of Surgical Outcomes of Petroclival Meningiomas with Clinico-Radiological Parameters, Molecular and Chromosomal Alterations. (PubMed, World Neurosurg)
    T2 hypointense tumor and brainstem edema on preoperative imaging are significant predictors of STR. H3K27me3 loss and hemizygous CDKN2A deletion may be associated with cavernous sinus extension, suggesting their role in tumor spread.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    CDKN2A deletion • SMO W535L
    almost2years
    Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial. (PubMed, PLoS One)
    Our recent clinical trial highlighted the utility of vismodegib for preserving visual organs in opBCC patients: 67% of patients displayed a complete response histologically...In the age of targeted therapies, linking molecular genetic analysis to prospective clinical trials may be necessary to provide mechanistic understanding of clinical outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT02436408.
    Journal
    |
    SMO (Smoothened Frizzled Class Receptor) • GLI1 (GLI Family Zinc Finger 1)
    |
    SMO mutation • SMO W535L
    |
    Erivedge (vismodegib)
    over2years
    Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma. (PubMed, CNS Neurosci Ther)
    Taken together, our work described SMO-related transcriptomes, metabolomes, and interactomes under different SMO status and treatment conditions, identifying CK2 and AKT as therapeutic targets for SHH-subtype MB cells with SMO inhibitor resistance.
    Journal
    |
    SMO (Smoothened Frizzled Class Receptor)
    |
    SMO mutation • SMO W535L